As of 2026-09-21, the Intrinsic Value of GT Biopharma Inc (GTBP) is -2.49 USD. This GTBP valuation is based on the model Peter Lynch Fair Value. With the current market price of 7.16 USD, the upside of GT Biopharma Inc is -134.78%.
Based on its market price of 7.16 USD and our intrinsic valuation, GT Biopharma Inc (GTBP) is overvalued by 134.78%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -2.49 - -2.49 | -2.49 | -134.78% |
| P/E | (415.35) - (710.85) | (467.54) | -6629.9% |
| DDM - Stable | (128.37) - (405.12) | (266.74) | -3825.5% |
| DDM - Multi | (69.45) - (173.44) | (99.53) | -1490.1% |
| Market Cap (mil) | 10.03 |
| Beta | 1.47 |
| Outstanding shares (mil) | 1.40 |
| Enterprise Value (mil) | 5.07 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.05% |
| Cost of Debt | 5.00% |
| WACC | 6.86% |